CancerNetwork Members: Login | Register
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » PSA Screening

ONCOLOGY. Vol. 13 No. 6
 

Stable PSA Periods After adiation Therapy May Predict Disease-Free Survival

June 1, 1999

Like pretreatment prostate-specific antigen (PSA), post-treatment PSA nadirs may have prognostic significance in patients with prostate carcinoma, according to data presented by Timothy S. Boyd, MD, Robert C. Orth, BS, Wolfgang A. Tomé, PhD, and Mark A. Ritter, MD, PhD, of the Department of Human Oncology at the University of Wisconsin at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting.

Assuming that a stable PSA period occurring many years after treatment equates with cure, the investigators focused on the extent to which the probability of long-term cure decreased as the time between treatment and the observed stable PSA interval decreased.

The Wisconsin researchers reviewed the PSA records of 296 patients with prostate cancer initially treated with radiation therapy over a 9-year period. The final selection criteria for the study included definitive treatment with irradiation, no post-treatment use of antiandrogen therapy, and at least a 1-year period of stable PSA values (defined two or more values below 1.0 or 0.5 ng/mL).

Any subsequent deviation from these criteria was defined as the onset of biochemical failure. Clinical failures were defined by physical examination and biopsy or imaging. From the time of completion of each of the stable PSA periods, actuarial biochemical disease-free survival was then calculated.

Study Findings

Patients with stable PSA periods below 1.0 ng/mL beginning 1 to 2 years after radiation therapy had a 5-year postinterval control rate of 69%, increasing to 100% for stable PSA periods beginning 3 to 4 years after treatment. Patients with stable PSA periods below 0.5 ng/mL beginning 1 to 2 years after therapy had a 5-year postinterval control rate of 92%, increasing to 100% for stable PSA periods beginning 2 to 3 years after treatment. Patients in the nadir cohort achieved a 5-year post nadir control rate of only 72% for nadirs £ 1.0 ng/mL and a control rate of 73% for nadirs £ 0.5 ng/mL.

Therefore, the investigators concluded that PSA stability after radiation is prognostically significant and may be useful as a study end point and in counseling patients.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.







 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Psa Screening
Evidence on Psa Screening
Guidelines on Psa Screening
Patient Education on Psa Screening
Clinical Trials on Psa Screening
Practical Articles on Psa Screening
Research and Reviews on Psa Screening
All "Psa Screening" results

CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy